Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer

Matthew Wagner; Mark Garzotto; Dianne Lemmon; Kristine M. Eilers; Tomasz (Tom) Beer

doi:10.1016/j.urology.2004.10.059

Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer

Matthew Wagner, Mark Garzotto, Dianne Lemmon, Kristine M. Eilers, Tomasz (Tom) Beer

Urology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.

Original language	English (US)
Pages (from-to)	799.e37-799.e39
Journal	Urology
Volume	65
Issue number	4
DOIs	https://doi.org/10.1016/j.urology.2004.10.059
State	Published - Apr 2005

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.urology.2004.10.059

Cite this

@article{bbfcbc557a3744f291d4bbd3576a5e2a,

title = "Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer",

abstract = "A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.",

author = "Matthew Wagner and Mark Garzotto and Dianne Lemmon and Eilers, {Kristine M.} and Beer, {Tomasz (Tom)}",

year = "2005",

month = apr,

doi = "10.1016/j.urology.2004.10.059",

language = "English (US)",

volume = "65",

pages = "799.e37--799.e39",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer

AU - Wagner, Matthew

AU - Garzotto, Mark

AU - Lemmon, Dianne

AU - Eilers, Kristine M.

AU - Beer, Tomasz (Tom)

PY - 2005/4

Y1 - 2005/4

N2 - A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.

AB - A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=17144423283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144423283&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.10.059

DO - 10.1016/j.urology.2004.10.059

M3 - Article

C2 - 15833548

AN - SCOPUS:17144423283

SN - 0090-4295

VL - 65

SP - 799.e37-799.e39

JO - Urology

JF - Urology

IS - 4

ER -

Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this